

Table (1) Patients characteristic in concomitant and sequential boost groups

Variable	Concomitant boost N=24	Sequential boost N=24	P value
Age/years			
Mean $\pm$ SD	45.92 $\pm$ 7.37	50.17 $\pm$ 10.82	0.12
Median (range)	46 (27-60)	51 (33-65)	
Site			
Right	13 (54.17%)	7 (29.17%)	0.08
Left	11 (45.83%)	17 (70.83%)	
Quadrant			
Lower inner	4 (16.67%)	2 (8.33%)	0.14
Lower outer	2 (8.33%)	7 (29.17%)	
Supra areolar	3 (12.50%)	1 (4.17%)	
Upper inner	1 (4.17%)	4 (16.67%)	
Upper outer	14 (58.33%)	10 (41.67%)	
Pathology			
IDCA	24 (100%)	24 (100%)	1.00
Tumor grade			
2	22 (91.67%)	23 (95.83%)	1.00
3	2 (8.33%)	1 (4.17%)	
Tumor size			
Mean $\pm$ SD	2.70 $\pm$ 0.77	2.66 $\pm$ 0.79	0.85
Median (range)	2.75 (1.5-4)	2.5 (1-4)	
Number of positive LN			
Mean $\pm$ SD			0.47
Median (range)	1 $\pm$ 1.28 0 (0-3)	1.25 $\pm$ 1.26 1 (0-3)	
Number of removed LN			
Mean $\pm$ SD			0.003
Median (range)	22.08 $\pm$ 6.20 22 (12-39)	16.29 $\pm$ 5.66 14 (6-25)	
Estrogen receptors			
Negative	5 (20.83%)	8 (33.33%)	0.33
Positive	19 (79.17%)	16 (66.67%)	
Progesterone receptors			
Negative	7 (29.17%)	8 (33.33%)	0.76
Positive	17 (70.83%)	16 (66.67%)	
HER2			
Negative	17 (70.83%)	17 (70.83%)	1.00
Positive	7 (29.17%)	7 (29.17%)	

Table (2) skin toxicity in concomitant and sequential radiotherapy boost groups

Variable	Concomitant boost N=24	Sequential boost N=24	P value
Acute skin toxicity			
G0	8 (33.33%)	4 (16.67%)	0.18
G1 dry desquamation	10 (41.67%)	6 (25.00%)	
G1 mild erythema	3 (12.50%)	3 (12.50%)	
G2 tender erythema	2 (8.33%)	4 (16.67%)	
G3 moist desquamation	1 (4.17%)	6 (25.00%)	
G4 ulceration	0	1 (4.17%)	
Late skin toxicity 12ms			
G0	8 (33.33%)	5 (20.83%)	0.19
G1	5 (20.83%)	3 (12.50%)	
G2	10 (41.66%)	16 (66.67%)	
G3	1 (4.17%)	0	
Late skin toxicity 24ms			
	N=22	N=22	0.24
G0	16 (72.73%)	14 (54.55%)	
G1	2 (9.09%)	7 (31.82%)	
G2	4 (18.19%)	3 (13.64%)	

Table (3) lung and heart toxicity in concomitant and sequential radiotherapy boost groups

Variable	Concomitant boost N=24	Sequential boost N=24	P value
Acute lung toxicity			
G0	23 (95.83%)	23 (95.83%)	1.00
G2 cough dyspnea	1 (4.17%)	1 (4.17%)	
Late lung toxicity			
G0	23 (95.83%)	21 (87.50%)	0.30
G3 dense radiograph	1 (4.17%)	3 (12.50%)	
Heart toxicity			
No	22 (91.67%)	20 (83.33%)	0.38
Yes	2 (8.33%)	4 (16.67%)	

Table (4) Arm lymphedema in concomitant and sequential radiotherapy boost groups

Variable	Concomitant boost N=24	Sequential boost N=24	P value
Arm lymphedema before RT			
G0	22 (91.67%)	24 (100%)	0.15
G1 mild lymphedema	2 (8.33%)	0	
Arm lymphedema after 12 ms of RT			
G0	19 (79.17%)	22 (91.67%)	0.24
G1 mild lymphedema	2 (8.33%)	1 (4.17%)	
G2 moderate lymphedema	3 (12.50%)	1 (4.17%)	
Arm lymphedema after 24 ms of RT			
	N=22	N=22	0.37
G0	21 (95.45%)	21 (95.45%)	
G2 moderate lymphedema	1 (4.55%)	0	
G3 severe lymphedema	0	1 (4.55%)	

Table (5) Follow up and fate in concomitant and sequential radiotherapy boost groups

Variable	Concomitant boost N=24	Sequential boost N=24	P value
Time from diagnosis to death/end of study Mean ± SD Median (range)	3.65±0.82 3.70 (2.04-4.86)	3.45±0.82 3.50 (1.76-4.69)	0.42
Death No Yes	22 (91.67%) 2 (8.33%)	21 (87.50%) 3 (12.50%)	1.00
Time from surgery to recurrence/end of study Mean ± SD Median (range)	3.47±1.03 3.68 (1.20-4.80)	3.19±1.08 3.42 (1.05-4.69)	0.36
Recurrence All Local Distance Nodal	3 (12.50%) 0 3 (12.50%) 0	5 (20.83%) 0 4 (16.67%) 1 (4.17%)	0.44 1.00 1.00 1.00